Charlotte Charpentier
Overview
Explore the profile of Charlotte Charpentier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
231
Citations
2345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berkell M, Gorska A, Smet M, Bachelet D, Gentilotti E, Guedes M, et al.
Euro Surveill
. 2025 Mar;
30(10).
PMID: 40084424
BackgroundEvolution of SARS-CoV-2 is continuous.AimBetween 01/2020 and 02/2022, we studied SARS-CoV-2 variant epidemiology, evolution and association with COVID-19 severity.MethodsIn nasopharyngeal swabs of COVID-19 patients (n = 1,762) from France, Italy,...
2.
Charpentier C, Berzow D, Le Hingrat Q, Kaiser R, Gomes P, Miranda A, et al.
Clin Infect Dis
. 2025 Mar;
PMID: 40071658
Human immunodeficiency virus type 2 (HIV-2) is an attenuated retroviral infection characterized by specific natural susceptibility to antiretroviral drugs and acquired resistance profiles. Based on the latest knowledge of phenotypic...
3.
Brun J, Bergeron C, Averous G, Ardaens K, Aynaud O, Baffet H, et al.
Gynecol Obstet Fertil Senol
. 2025 Jan;
53(2):54-75.
PMID: 39884805
Objective: To update the recommendations issued by the National Cancer Institute (INCa) on the management of women with abnormal cervical cytology. Methods: INCa recommendations on the management of women with...
4.
Wirden M, Abdi B, Lambert-Niclot S, Chaix M, De Monte A, Montes B, et al.
J Antimicrob Chemother
. 2025 Jan;
80(3):692-696.
PMID: 39786501
Background: The S147G mutation is associated with high-level resistance to the integrase strand transfer inhibitor (INSTI) elvitegravir. In several poorly documented cases, it was also selected in patients on dolutegravir....
5.
van Kampen J, van Nood E, Mahmud R, Krullaars Z, Voskamp T, Voskamp M, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae705.
PMID: 39741997
Background: The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors. Integrase strand transfer...
6.
Montrouge T, Bertine M, Peytavin G, Saint Joannis T, Bachelard A, De Truchis P, et al.
Clin Infect Dis
. 2024 Dec;
PMID: 39737782
Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with...
7.
Marcelin A, Soulie C, Wirden M, Barriere G, Durand F, Charpentier C, et al.
J Antimicrob Chemother
. 2024 Oct;
80(1):95-101.
PMID: 39436753
Background: Second-generation integrase strand transfer inhibitors (InSTIs) have a high barrier to resistance and potent antiretroviral activity. They are recommended as first- or second-line (FL and SL) options in two-...
8.
Viral whole genome sequencing reveals high variations in APOBEC3 editing between HPV risk categories
Ferre V, Coppee R, Gbeasor-Komlanvi F, Vacher S, Bridier-Nahmias A, Bucau M, et al.
J Med Virol
. 2024 Oct;
96(10):e70002.
PMID: 39400339
High-risk human papillomavirus (HPV) infections are responsible for cervical cancer. However, little is known about the differences between HPV types and risk categories regarding their genetic diversity and particularly APOBEC3-induced...
9.
Serris A, Ferre V, Le Hingrat Q, Bachelard A, Charpentier C, Exarchopoulos M, et al.
J Antimicrob Chemother
. 2024 Sep;
79(11):2932-2938.
PMID: 39287977
Introduction: Cabotegravir, an integrase strand transfer inhibitor, and rilpivirine, an NNRTI, constitute the first long-acting (LA), injectable, two-drug ART regimen approved for the maintenance of virological suppression in persons living...
10.
Joly V, Ferre V, Le Hingrat Q, Peytavin G, Cresta M, Charpentier C, et al.
Clin Infect Dis
. 2024 Sep;
PMID: 39283963
This retrospective study evaluated Bictegravir/FTC/TAF in 24 PWHIV, 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load < 40 copies/mL....